Page last updated: 2024-12-06

prenalterol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Prenalterol is a synthetic beta-adrenergic receptor agonist with a high affinity for beta-1 receptors, leading to an increase in heart rate and contractility. It has been studied for its potential therapeutic effects in heart failure and as a treatment for bradycardia. Prenalterol's synthesis involves several steps, including the reaction of 3-amino-4-hydroxybenzophenone with 2-chloro-1-phenylethanol. It is important to note that prenatalterol has been associated with adverse effects such as arrhythmias and hypertension, which have limited its clinical use.'

Prenalterol: A partial adrenergic agonist with functional beta 1-receptor specificity and inotropic effect. It is effective in the treatment of acute CARDIAC FAILURE, postmyocardial infarction low-output syndrome, SHOCK, and reducing ORTHOSTATIC HYPOTENSION in the SHY-RAGER SYNDROME. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID42396
CHEMBL ID1160714
CHEBI ID8391
SCHEMBL ID249753
MeSH IDM0017537

Synonyms (34)

Synonym
gtpl537
hyprenan
prenalterol [inn:ban]
brn 5740338
cgp 7760b
einecs 260-791-5
(s)-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenol
prenalterolum [inn-latin]
phenol, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, (s)-
57526-81-5
C07533
prenalterol
4-[(2s)-2-hydroxy-3-(propan-2-ylamino)propoxy]phenol
CHEMBL1160714
phenol metabolite
chebi:8391 ,
m4g34404cx ,
unii-m4g34404cx
prenalterolum
prenalterol [who-dd]
prenalterol [inn]
prenalterol [mi]
SCHEMBL249753
bdbm50421716
(s)-1-(4-hydroxyphenoxy)-3-(1-methylethyl)amino-2-propanol
ADUKCCWBEDSMEB-NSHDSACASA-N
(s)-4-(2-hydroxy-3-(isopropylamino)propoxy)phenol
4-[(2s)-2-hydroxy-3-(isopropylamino)propoxy]phenol
DTXSID8023507
DB13777
Q7240518
prenalterol is known as a beta1 adrenoreceptor agonist.
CS-0043280
HY-112071

Research Excerpts

Overview

Prenalterol is a new beta-adrenergic agonist which stimulates mainly beta 1-receptors, in contrast to isoprenaline which stimulates both beta 1 and 2-receptor. Unlike isoproterenol, it is both orally active and has a long duration of action.

ExcerptReferenceRelevance
"Thus prenalterol appears to be a useful drug in cardiogenic shock and further studies are warranted."( Prenalterol in cardiogenic shock following acute myocardial infarction.
Coma-Canella, I; Jadraque, LM; Lopez-Sendon, J, 1984
)
2.17
"Prenalterol is a new beta-adrenergic agonist which stimulates mainly beta 1-receptors, in contrast to isoprenaline which stimulates both beta 1- and beta 2-receptors. "( A comparison of the hemodynamic effects of prenalterol and isoprenaline in patients with complete heart block.
Bonde, J; Kampmann, JP; Lindeneg, O; Lønholt, C; Pelle, H; Svendsen, TL,
)
1.84
"Prenalterol is a beta 1-adrenergic agent."( Inotropic drugs and their mechanisms of action.
Scholz, H, 1984
)
0.99
"Prenalterol is an inotropic drug that has the effects of a full cardioselective beta-adrenoceptor agonist."( Cardioselectivity of prenalterol and isoproterenol.
Bobik, A; Hargreaves, M; Jennings, G; Korner, P; Oddie, C, 1983
)
1.31
"Prenalterol is an orally active cardioselective beta agonist, with a long half-life. "( A dose response study with oral prenalterol in patients with chronic congestive cardiac failure.
Besterman, EM; Comerford, MB; Hendry, WG, 1984
)
1.99
"Prenalterol (H 133/22) is an adrenergic beta-receptor stimulator which unlike isoproterenol is both orally active and has a long duration of action. "( Inotropic, chronotropic and dromotropic effects of prenalterol, a new cardiostimulant drug.
Aberg, G; Adler, G; Herrmann, I; Hodess, AB; Moore, EN; Spear, JF, 1982
)
1.96

Effects

Oral prenalterol has a beneficial short term haemodynamic effect in patients with severe heart failure.

ExcerptReferenceRelevance
"Oral prenalterol has a beneficial short term haemodynamic effect in patients with severe heart failure."( Acute haemodynamic effects of oral prenalterol in severe heart failure.
Goodfellow, RM; Ormerod, O; Petch, MC; Scott, C; Wisbey, C, 1984
)
1
"Prenalterol has the most pronounced haemodynamic effect on heart rate (increase 25-47%) and the heart rate-blood pressure-product (increase 54-81%)."( Metabolic effects of prenalterol in diabetic patients.
Oltmanns, D, 1982
)
1.3
"Oral prenalterol has a beneficial short term haemodynamic effect in patients with severe heart failure."( Acute haemodynamic effects of oral prenalterol in severe heart failure.
Goodfellow, RM; Ormerod, O; Petch, MC; Scott, C; Wisbey, C, 1984
)
1

Actions

Prenalterol was found to increase left ventricular maximum dP/dt in a dose-dependent manner up to a dose level of 50 micrograms/kg.

ExcerptReferenceRelevance
"Prenalterol produced an increase in cardiac index (p less than 0.01), mean aortic pressure (p less than 0.02), net work index (p less than 0.01), net/stroke work index (p less than 0.01), pressure rate product (p less than 0.05), and myocardial perfusion gradient (p less than 0.02)."( Prenalterol in cardiogenic shock following acute myocardial infarction.
Coma-Canella, I; Jadraque, LM; Lopez-Sendon, J, 1984
)
2.43
"Prenalterol was found to increase left ventricular maximum dP/dt in a dose-dependent manner up to a dose level of 50 micrograms/kg."( Inotropic, chronotropic and dromotropic effects of prenalterol, a new cardiostimulant drug.
Aberg, G; Adler, G; Herrmann, I; Hodess, AB; Moore, EN; Spear, JF, 1982
)
1.24

Treatment

Prenalterol pretreatment did not potentiate inotropic responses to methoxamine and CaCl2. The treatment with prenalterol had not altered the IHR.

ExcerptReferenceRelevance
"Prenalterol pretreatment did not induce any marked changes, either in the stimulatory potency or affinity of the agonists in the two tissues or in the maximal response (ISA) of prenalterol in the papillary muscle."( Effects of in vivo treatment with isoprenaline or prenalterol on beta-adrenoceptor mechanisms in the heart and soleus muscle of the cat.
Carlsson, E; Hedberg, A; Mattsson, H; Nerme, V, 1984
)
1.24
"Prenalterol pretreatment suppressed clonidine-induced ultrasound production at both doses."( Cardiovascular mediation of clonidine-induced ultrasound production in infant rats.
Blumberg, MS; Kent, KJ; Kreber, LA; Sokoloff, G, 2000
)
1.03
"Prenalterol pretreatment did not potentiate inotropic responses to methoxamine and CaCl2 and blocked (in accordance with beta-adrenoceptor occupation by a low-efficacy partial agonist) responses to norepinephrine (NE), tyramine, and to a certain extent ouabain."( A method to assess concomitant cardiac phosphodiesterase inhibition and positive inotropy.
Kenakin, TP; Scott, DL, 1987
)
0.99
"The treatment with prenalterol had not altered the IHR."( Influence of long-term beta receptor stimulation with prenalterol on intrinsic heart rate in rats.
Dahlström, U; Nylander, E, 1984
)
0.83

Pharmacokinetics

ExcerptReferenceRelevance
" Prenalterol was extensively distributed to extravascular tissues with a half-life of the distribution phase close to 7 min."( Pharmacokinetic studies in man of the selective beta 1-adrenoceptor agonist, prenalterol.
Graffner, C; Hoffmann, KJ; Johnsson, G; Lundborg, P; Rönn, O, 1981
)
1.4
" The half-life of the elimination phase is close to 2 hours."( Pharmacokinetics of prenalterol in healthy subjects and patients with congestive heart failure.
Rönn, O, 1982
)
0.59

Bioavailability

ExcerptReferenceRelevance
" The drug was well absorbed from the gastrointestinal tract and most of the administered radioactivity was excreted in urine from all species within 24 hr."( The metabolic disposition of the selective beta 1-adrenoceptor agonist prenalterol in mice, rats, dogs, and humans.
Arfwidsson, A; Borg, KO; Hoffmann, KJ,
)
0.36
" The extent of bioavailability after administration of prenalterol as a solution is about 25% of an intravenous dose."( Pharmacokinetics of prenalterol in healthy subjects and patients with congestive heart failure.
Rönn, O, 1982
)
0.84
" Oral bioavailability averaged 33% and was independent of dose."( Cardioselectivity of prenalterol and isoproterenol.
Bobik, A; Hargreaves, M; Jennings, G; Korner, P; Oddie, C, 1983
)
0.58
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31

Dosage Studied

The dose-response curves of the beta-adrenergic agonists isoprenaline (mixed beta 1 and beta 2), prenalterol (beta 1-selective) and noradrenaline were studied on adipose cells of the rat. In 5- and 10-day-old animals, pren alterol treatment produced minimal stimulation of PRA and the dose- response curve was essentially flat.

ExcerptRelevanceReference
" Redetermination of the dose-response function for clenbuterol, following 2 weeks of repeated daily administration, showed that clenbuterol no longer affected DRL behavior at doses up to 3 mg/kg."( Behavioral effects of beta adrenergic agonists and antidepressant drugs after down-regulation of beta-2 adrenergic receptors by clenbuterol.
O'Donnell, JM, 1990
)
0.28
" In 5- and 10-day-old animals, prenalterol treatment produced minimal stimulation of PRA and the dose-response curve was essentially flat."( Effects of sympathetic activation on plasma renin activity in the developing rat.
Johnson, AK; Kirby, RF, 1990
)
0.57
"When dose-response curves are replicated, averaging the responses to each dose of drug reduces the slope of the mean curve."( A method for presenting and comparing dose-response curves.
Carpenter, JR, 1986
)
0.27
" Dose-response curves were also carried out for intravenous prenalterol, a partial beta 1-adrenergic agonist."( Age and sex differences in cardiovascular reactivity to adrenergic agonists, mental stress and isometric exercise in normal subjects.
Hjalmarson, A; Johansson, SR, 1988
)
0.52
" and oral dosing has been studied."( The pharmacokinetics of oral and intravenous prenalterol in young, healthy volunteers.
Clarke, AF; Jack, DB; Kendall, MJ; Smith, SR,
)
0.39
" Because of delayed renal elimination of the drug, daily dosage must be reduced to prevent symptoms of adrenergic stimulation."( Haemodynamic effects of prenalterol in patients on dialysis.
Lustenberger, N, 1982
)
0.57
" What remains to be solved is the dosage level."( Clinical experiences with prenalterol as an antidote to Beta-adrenoceptor blockade.
Kulling, P, 1982
)
0.56
" Moreover, dose-response analysis indicates these salutary improvements can be maximally produced by the small dose of 1 mg obviating the need for larger doses."( The hemodynamic actions of prenalterol in left ventricular failure.
Awan, NA; Evenson, MK; Mason, DT; Needham, KE, 1982
)
0.56
"The dose-response curves of the beta-adrenergic agonists isoprenaline (mixed beta 1 and beta 2), prenalterol (beta 1-selective), noradrenaline (more beta 1 than beta 2) and salbutamol (beta 2-selective) were studied on adipose cells of the rat, in vitro."( Characterization of the beta-adrenoceptor of the adipose cell of the rat.
Curtis-Prior, PB; Tan, S, 1983
)
0.48
" The dosage was reduced to 30 mg four times daily because of the development of complex ventricular premature beats."( Effect of prenalterol on orthostatic hypotension in the Shy-Drager syndrome.
Fagard, R; Goovaerts, J; Knockaert, D; Verfaillie, C, 1984
)
0.67
" Three days post-AMI the dose-response curve for isoproterenol of right ventricular dP/dtmax was significantly depressed, while the inotropic effect of impromidine was not impaired."( Apparent superiority of H2-receptor stimulation and simultaneous beta-blockade over conventional treatment with beta-sympathomimetic drugs in post-acute myocardial infarction: cardiac effects of impromidine--a new specific H2-receptor agonist-in the survi
Baumann, G; Blömer, H; Felix, SB; Heidecke, CD; Loher, U; Ludwig, L; Riess, G, 1984
)
0.27
" Prenalterol dosage was simple and could be guided by blood pressure response."( Massive metoprolol poisoning treated with prenalterol.
Hulting, J; Wallin, CJ, 1983
)
1.44
" Dose-response studies in five patients showed dose-dependent increments in hemodynamic variables, while hormonal changes plateaued at the second dose level."( Hemodynamic, hormonal and electrolyte responses to prenalterol infusion in heart failure.
Espiner, EA; Fitzpatrick, D; Ikram, H; Nicholls, MG, 1983
)
0.52
" The proposed method was applied successfully to the determination of prenalterol hydrochloride either in the pure form or in its dosage forms."( Polarographic determination of prenalterol hydrochloride through treatment with nitrous acid.
Aly, FA; Belal, F; Walash, MI, 1995
)
0.81
"A simple and highly sensitive fluorimetric method was developed for the routine determination of prenalterol hydrochloride in bulk, in dosage forms and in biological fluids."( Spectrofluorimetric determination of prenalterol hydrochloride in pharmaceutical preparations and biological fluids.
Aly, FA, 1999
)
0.79
" The method was applied successfully in determining the drugs in dosage forms and in biological fluids."( Determination of phenolic sympathomimetic drugs in pharmaceutical samples and biological fluids by flow-injection chemiluminescence.
Al-Tamimi, SA; Alwarthan, AA; Aly, FA,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-2 adrenergic receptor Bos taurus (cattle)Kd1.07200.00061.47759.1200AID40694
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
POU domain, class 2, transcription factor 1Homo sapiens (human)Km13.30002.10005.39008.6000AID1769498
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (11)

Processvia Protein(s)Taxonomy
negative regulation of DNA-templated transcriptionPOU domain, class 2, transcription factor 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionPOU domain, class 2, transcription factor 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIPOU domain, class 2, transcription factor 1Homo sapiens (human)
positive regulation of miRNA transcriptionPOU domain, class 2, transcription factor 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIPOU domain, class 2, transcription factor 1Homo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptor Bos taurus (cattle)
regulation of smooth muscle contractionBeta-2 adrenergic receptor Bos taurus (cattle)
positive regulation of MAPK cascadeBeta-2 adrenergic receptor Bos taurus (cattle)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptor Bos taurus (cattle)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptor Bos taurus (cattle)
positive regulation of autophagosome maturationBeta-2 adrenergic receptor Bos taurus (cattle)
positive regulation of lipophagyBeta-2 adrenergic receptor Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPOU domain, class 2, transcription factor 1Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPOU domain, class 2, transcription factor 1Homo sapiens (human)
DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
protein bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
sequence-specific DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptor Bos taurus (cattle)
protein homodimerization activityBeta-2 adrenergic receptor Bos taurus (cattle)
norepinephrine bindingBeta-2 adrenergic receptor Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
nucleusPOU domain, class 2, transcription factor 1Homo sapiens (human)
nucleoplasmPOU domain, class 2, transcription factor 1Homo sapiens (human)
endoplasmic reticulumPOU domain, class 2, transcription factor 1Homo sapiens (human)
intracellular membrane-bounded organellePOU domain, class 2, transcription factor 1Homo sapiens (human)
chromatinPOU domain, class 2, transcription factor 1Homo sapiens (human)
RNA polymerase II transcription regulator complexPOU domain, class 2, transcription factor 1Homo sapiens (human)
early endosomeBeta-2 adrenergic receptor Bos taurus (cattle)
Golgi apparatusBeta-2 adrenergic receptor Bos taurus (cattle)
receptor complexBeta-2 adrenergic receptor Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID59673Effective dose required for the maximum heart rate in anesthetized dogs.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Beta-adrenoceptor stimulant properties of amidoalkylamino-substituted 1-aryl-2-ethanols and 1-(aryloxy)-2-propanols.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID59375Intrinsic sympathomimetic activity (ISA), calculated as the percent of maximum change in hind limb perfusion pressure (HLPP)1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Beta-adrenoceptor stimulant properties of amidoalkylamino-substituted 1-aryl-2-ethanols and 1-(aryloxy)-2-propanols.
AID48166Intrinsic activity as percentage of heart rate (HR max) in cat was determined1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Adrenergic receptor agonists. Benzofuranylethanolamines.
AID1769499Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring Vmax incubated for 2 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID40531Positive inotropic effects by direct or indirect beta-1 adrenergic receptor activation.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
In search of the digitalis replacement.
AID40694Affinity for cow beta-2 adrenergic receptor by measuring displacement (-)-[3H]dihydroalprenolol (DHA)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
AID234276Selectivity is expressed as the ratio of ED50 on hind limb perfusion pressure to the ED50 on heart rate1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Beta-adrenoceptor stimulant properties of amidoalkylamino-substituted 1-aryl-2-ethanols and 1-(aryloxy)-2-propanols.
AID59674Effective dose required for the maximum hind limb perfusion pressure(HLPP) in anesthetized dogs.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Beta-adrenoceptor stimulant properties of amidoalkylamino-substituted 1-aryl-2-ethanols and 1-(aryloxy)-2-propanols.
AID218848Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the Chang living cells1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID41943Dose necessary to produce 50% of the isoprenaline effect to inhibit GDP binding to beta-3 adrenergic receptor in brown adipose tissue (BAT mitochondria) of rats after subcutaneous administration.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Selective beta 3-adrenergic agonists of brown adipose tissue and thermogenesis. 1. [4-[2-[(2-Hydroxy-3-phenoxypropyl)amino]ethoxy]phenoxy]acetates.
AID1769501Ratio of drug uptake in human OCT1 expressing HEK293 cells at 2.5 uM to drug uptake in empty vector transfected human HEK293 cells at 2.5 uM2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID70530Free energy of binding to turkey erythrocyte beta receptor1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Mapping the turkey erythrocyte beta receptor: a distance geometry approach.
AID1769498Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring Km incubated for 2 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID218845Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the membranes of bovine skeletal muscle preparation1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID29812Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID48549Tested for agonistic effect on heart rate against beta-1 adrenergic receptor in cat1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Adrenergic receptor agonists. Benzofuranylethanolamines.
AID59374Intrinsic sympathomimetic activity (ISA, calculated as the percent of maximum change in heart rate (HR)1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Beta-adrenoceptor stimulant properties of amidoalkylamino-substituted 1-aryl-2-ethanols and 1-(aryloxy)-2-propanols.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID40686Affinity for cow beta-2 adrenergic receptor by measuring displacement (-)-[3H]dihydroalprenolol (DHA)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1769500Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring intrinsic clearance incubated for 2 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID235308Ratio of the dose (D500,subcutaneous administration) elevating the rat heart rate to 500 bpm to the GDP ED501992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Selective beta 3-adrenergic agonists of brown adipose tissue and thermogenesis. 1. [4-[2-[(2-Hydroxy-3-phenoxypropyl)amino]ethoxy]phenoxy]acetates.
AID1346260Human beta1-adrenoceptor (Adrenoceptors)1999Molecular pharmacology, Nov, Volume: 56, Issue:5
Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtype-selective agonists.
AID1346260Human beta1-adrenoceptor (Adrenoceptors)1989Molecular pharmacology, Mar, Volume: 35, Issue:3
Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (289)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990257 (88.93)18.7374
1990's24 (8.30)18.2507
2000's7 (2.42)29.6817
2010's0 (0.00)24.3611
2020's1 (0.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.13 (24.57)
Research Supply Index5.86 (2.92)
Research Growth Index3.94 (4.65)
Search Engine Demand Index42.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials38 (12.18%)5.53%
Reviews10 (3.21%)6.00%
Case Studies16 (5.13%)4.05%
Observational0 (0.00%)0.25%
Other248 (79.49%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]